All Categories Archives - Page 300 of 306

Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH

Christina A. Eichstaedt, Catharina Belge, Wendy K. Chung, Stefan Gräf, Ekkehard Grünig, David Montani, Rozenn Quarck, Jair A. Tenorio-Castano, Florent Soubrier, Richard C. Trembath, Nicholas W. MorrellHeidelberg University Hospital. University of Leuven. Columbia University. University of Cambridge. Université Paris-Saclay. Hôpital Marie Lannelongue. Hospital Universitario La Paz. Centro de Investigación Biomédica en Red de Enfermedades Raras.

Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH Read More »

Comparison of living-donor lobar lung transplantation and cadaveric lung transplantation for pulmonary hypertension

Hidenao Kayawake, Satona Tanaka, Yoshito Yamada, Shiro Baba, Hideyuki Kinoshita, Kazuhiro Yamazaki, Tadashi Ikeda, Kenji Minatoya, Yojiro Yutaka, Masatsugu Hamaji, Akihiro Ohsumi, Daisuke Nakajima, Hiroshi DateKyoto University. Kobe City Medical Center General Hospital.Japan European Journal of Cardiothoracic SurgeryEur J Cardiothorac Surg 2023; DOI: 10.1093/ejcts/ezad024 AbstractObjectives: Living-donor lobar lung transplantation (LDLLT) is a life-saving procedure for critically ill

Comparison of living-donor lobar lung transplantation and cadaveric lung transplantation for pulmonary hypertension Read More »

Ambrisentan for in pediatric pulmonary arterial hypertension: a cost-utility analysis

Jefferson Antonio Buendia, Diana Guerrero Patino, Erika Fernanda LindarteUniversity of Antioquia.Columbia Pediatric PulmonologyPediatr Pulmonol 2023; DOI: 10.1002/ppul.26361 AbstractIntroduction: Despite the growing evidence of efficacy, little is known regarding the efficiency of ambrisentan to decrease cost and improve the functional classes of pediatric patients with Pulmonary arterial hypertension. This study aims to determine the cost-utility of ambrisentan regarding

Ambrisentan for in pediatric pulmonary arterial hypertension: a cost-utility analysis Read More »

Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients

Ali Ahmadi, Jennifer M. Renaud, Steven Promislow, Ian G. Burwash, Girish Dwivedi, Ran Klein, Jason G. E. Zelt, Robert A. deKamp, Rob S. Beanlands, Lisa M. MielniczukUniversity of Ottawa.Canada Journal of Nuclear CardiologyJ Nucl Cardiol 2021; 28: 2784-2795DOI: 10.1007/s12350-020-02144-x AbstractBackground: Reduced left ventricular (LV) function is associated with increased myocardial oxygen consumption rate (MVO2) and altered sympathetic

Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients Read More »

Right Ventricular Maladaptation to Pressure Overload in Fischer Rats Is Associated With Profound Deficiency in Adenylate Kinase 1 and Impaired Ventricular Energetics

Jason G. E. Zelt, Virgilio Cadete, Yupu Deng, Rafael Godoy, Alexanne Cuillerier, Katelynn Rowe, Mohammad Abdul-Ghani, Lynn Megeney, Yan Burelle, Antonio Giulivi, Alexandre F. R. Stewart, Steeve Provencher, Sandra Breuils-Bonnet, Sébastien Bonnet, Robert deKemp, Rob Beanlands, Lisa M. Mielniczuk, Duncan J. StewartUniversity of Ottawa.Canada HypertensionHypertension 2022; 79: 2774-2786DOI: 10.1161/HYPERTENSIONAHA.122.19300 AbstractBackground: We explored the mechanism of maladaptive right

Right Ventricular Maladaptation to Pressure Overload in Fischer Rats Is Associated With Profound Deficiency in Adenylate Kinase 1 and Impaired Ventricular Energetics Read More »

Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension

Hythem Nawaytou, Nancy K. Hills, Ronald I. ClymanUniversity of California San Francisco.United States Pediatric ResearchPediatr Res 2023; DOI: 10.1038/s41390-023-02522-4 AbstractBackground: The aim of the study was to determine whether prolonged exposure to a moderate/large patent ductus arteriosus left-to-right shunt (PDA) increases the risk of late (beyond 36 weeks) pulmonary hypertension (BPD-PH) and pulmonary vascular disease (BPD-PVD) during

Patent ductus arteriosus and the risk of bronchopulmonary dysplasia-associated pulmonary hypertension Read More »

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience

David Edward Youssef, Stephanie S. Handler, Susan Marjorie Richards, Catherine Anne Sheppard, Jenna Smith, Kathryn Tillman, Matthew Pietrosanu, Edward Kirkpatrick, Angela Bates University of Alberta and Stollery Children’s Hospital. Medical College of Wisconsin.Canada and United States Frontiers in PediatricsFront Pediatr 2023; DOI: 10.3389/fped.2023.1055131 AbstractIntroduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience Read More »

Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study

Azza Tantawy, Nayera El‑Sherif, Sara Makkeyah, Nahed Salah Eldeen, Noura Bahaa El‑Din Farghal, Nanies Soliman, Fatma S. E. EbeidAin Shams University.Egypt Annals of HematologyAnn Hematol 2023; 102: 271-281DOI: 10.1007/s00277-023-05099-4 AbstractSleep disordered breathing (SDB) is a common underdiagnosed sequela of sickle cell disease (SCD) that has been linked to the frequency of vaso-occlusive crises. To determine the frequency of SDB in children with SCD and its association to SCD-related

Sleep disordered breathing and its relation to stroke and pulmonary hypertension in children with sickle cell disease: a single-center cross-sectional study Read More »

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension

Stefan Willmann, Andrea Kerstin Keller, Michaela Meyer, Dorina van der Mey, Gagriela Wirsching, Yang Zhang, Henk-Jan Drenth, Anne Keunecke, Esmée Vendel, Soundos SalehBayer AG. LAP&P Consultants.Germany Pediatric PulmonologyPediatr Pulmonol 2023; 58: 908-917DOI: 10.1002/ppul.26277 AbstractBackground: The PATENT-CHILD study investigated riociguat in children aged ≥ 6 to <18 years with pulmonary arterial hypertension (PAH) treated with tablets or an

Population pharmacokinetics of riociguat in a pediatric population (aged ≥ 6 years) with pulmonary arterial hypertension Read More »